Adina Hutanu

Dr. Adina Hutanu

“George Emil Palade” University of Medicine, Pharmacy, Science and Technology Faculty of Medicine, Department of Laboratory Medicine, 38 Ghe Marinescu Tîrgu Mureș, Romania
+1
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Cytokine
Verified
Journal Article
Closed access
CMCristina Oana Mărginean
Cristina Oana Mărginean
Lorena Elena MelitLorena Elena Melit
Lorena Elena Melit
AHAdina Hutanu
Adina Hutanu
DGDana Valentina Ghiga
Dana Valentina Ghiga
MSMaria Oana Săsăran
Maria Oana Săsăran

14 March 2020 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AGAnca Georgescu
Anca Georgescu
CBClaudia Bănescu
Claudia Bănescu
RARazvan Azamfirei
Razvan Azamfirei
AHAdina Hutanu
Adina Hutanu
VMValeriu Moldovan
Valeriu Moldovan
LALeonard Azamfirei
Leonard Azamfirei
Background: The goal of the study was to evaluate a potential role for tumor necrosis factor alpha (TNF-α) genetic variability as biomarker in sepsis. In particular, we aimed to determine if single nucleotide polymorphisms (SNPs) ofTNF-αgene are associated with sepsis in terms of risk, severity and outcome.Methods: We performed a prospective study on 163 adult critically ill septic patients (septic shock 65, sepsis 98, further divided in 40 survivors and 123 deceased) and 232 healthy controls. Genotyping ofTNF-αSNPs (-308G/A, -238G/A, -376G/A and +489G/A) was performed for all patients and controls and plasma cytokine levels were measured during the first 24 h after sepsis onset.Results: TNF-α +489G/A A-allele carriage was associated with significantly lower risk of developing sepsis and sepsis shock (AA+AG vs GG: OR = 0.53;p = 0.004; 95% CI = 0.34–0.82 and OR = 0.39;p = 0.003; 95% CI = 0.21–0.74, respectively) but not with sepsis-related outcomes. There was no significant association between any of the otherTNF-αpromoter SNPs, or their haplotype frequencies and sepsis or septic shock risk. Circulating TNF-α levels were higher in septic shock; they were not correlated with SNP genotype distribution; GG homozygosity for each polymorphism was correlated with higher TNF-α levels in septic shock.Conclusions: TNF-α +489G/A SNP A-allele carriage may confer protection against sepsis and septic shock development but apparently does not influence sepsis-related mortality. PromoterTNF-αSNPs did not affect transcription and were not associated with distinct sepsis, septic shock risk or outcomes.

Verified
Journal Article
Open access
PDF file
RIRăzvan Marius Ion
Răzvan Marius Ion
MSMelania Sibianu
Melania Sibianu
AHAdina Hutanu
Adina Hutanu
FBFelicia Gabriela Beresescu
Felicia Gabriela Beresescu
DSDaniela Tatiana Sala
Daniela Tatiana Sala
RNRadu Mircea Neagoe
Radu Mircea Neagoe
At present, obesity, as a part of metabolic syndrome, represents the leading factor for disability, and is correlated with higher inflammation status, morbidity, and mortality. The purpose of our study is to add new insights to the present body of knowledge regarding the correlations between chronic systemic inflammation and severe obesity, which cannot be treated without considering other metabolic syndrome conditions. Biomarkers of high-level chronic inflammation are recognized as important predictors of pro-inflammatory disease. Besides the well-known pro-inflammatory cytokines, such as WBCs (white blood cells), IL-1 (interleukin-1), IL-6 (interleukin-6), TNF-alpha (tumor necrosis factor-alpha), and hsCRP (high-sensitivity C-reactive protein), as well as anti-inflammatory markers, such as adiponectin and systemic inflammation, can be determined by a variety of blood tests as a largely available and inexpensive inflammatory biomarker tool. A few parameters, such as the neutrophil-to-lymphocyte ratio; the level of cholesterol 25-hydroxylase, which is part of the macrophage-enriched metabolic network in adipose tissue; or levels of glutamine, an immune–metabolic regulator in white adipose tissue, are markers that link obesity to inflammation. Through this narrative review, we try to emphasize the influence of the weight-loss process in reducing obesity-related pro-inflammatory status and associated comorbidities. All data from the presented studies report positive results following weight-loss procedures while improving overall health, an effect that lasts over time, as far as the existing research data show.

21 June 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
AHAdina Hutanu
Adina Hutanu
Mihaela IancuMihaela Iancu
Mihaela Iancu
RBRodica Bălaşa
Rodica Bălaşa
SMSmaranda Maier
Smaranda Maier
MDMinodora Dobreanu
Minodora Dobreanu
In cerebral ischemia, evaluation of multiple biomarkers involved in various pathological pathways is a useful tool in assessing the outcome of the patients even from the early stages of the disease. In this study we investigated the utility of a panel of 5 peripheral biomarkers of inflammatory status, neuronal destruction and secondary fibrinolysis in the acute phase of ischemia, and evaluated the impact of these biomarkers on functional outcome after ischemic stroke. The 5 biomarkers (plasma CRP, D-Dimers, sTNFR-1, NGAL and NSE) were measured using a biochip array technology. Eighty nine patients in Romania were divided into 2 subgroups using the modified Rankin Scale evaluated at 3 months after ischemic stroke; the possible impact of analyzed biomarkers on unfavorable functional outcome was tested by binomial logistic regression. The subgroup with unfavorable outcome had higher concentrations of CRP, NGAL, sTNFR-1 and D-dimers, but CRP and NGAL values were not statistically different between the two subgroups. The univariate logistic regression analysis of plasma biomarkers revealed that CRP, D-Dimers, NGAL, sTNFR-1 were significant predictors of unfavorable clinical outcome. In the case of D-Dimers and sTNFR-1 we noticed an increased discrimination ability (versus baseline clinical model) to classify poor functional outcome with a tendency toward statistical signification. During the acute phase of the ischemic stroke, plasma concentrations of CRP, D-Dimers and sTNFR-1 were elevated in unfavorable outcome patients. D-Dimers and sTNFR-1 were independent predictors of poor outcome at 3 months after ischemic stroke. The biochip array technology offers the possibility to simultaneously measure several parameters involved in multiple pathophysiological pathways, in a small sample volume.

13 September 2018 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
SCSimona Cernea
Simona Cernea
ARAndrada Larisa Roiban
Andrada Larisa Roiban
EBEmőke Both
Emőke Both
AHAdina Hutanu
Adina Hutanu

3 December 2012 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
RBRodica Bălaşa
Rodica Bălaşa
ZBZoltan Bajko
Zoltan Bajko
AHAdina Hutanu
Adina Hutanu
Background: Interleukin-17 (IL-17), which is secreted by Th17 cells, is a proinflammatory cytokine that is implicated in the pathogenesis of multiple sclerosis (MS) and plays a role in nonresponse of MS patients to interferon-β (IFN-β) therapy. Objectives: The purpose of this study was to establish a correlation between nonresponders (NR) and IL-17A serum titers and binding antibodies (BAbs) to IFN-β, as well as to find a correlation between IL-17A serum levels and other features of MS patients. Methods: Our prospective study included 72 inactive relapsing–remitting multiple sclerosis (RRMS) patients that had been treated for at least 18 months with IFN-β and 15 healthy subjects. We determined the serum levels of IL-17A and of BAbs. IL-17A levels were considered elevated (IL-17A+) if the recorded value was greater than 1.6 pg/ml. Results: Twenty-seven patients (37.5%) were NR and had a significantly higher serum IL-17A level compared to the responders group. Nineteen patients (26.4%) were IL-17A+ and had had a significantly higher number of relapses in the previous year and a higher Expanded Disability Status Score. The majority of IL-17A+ patients were NR and had a shorter MS duration. Conclusions: RRMS patients with high serum IL-17A levels do not respond well to IFN-β therapy and have shorter MS duration compared to patients with low IL-17A levels. This response is not influenced by the presence of BAbs.